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Background: Acute kidney injury (AKI) is a clinically important condition that has attracted a great deal of interest
from the biomedical research community. However, acute kidney injury AKI research findings have yet to be
translated into significant changes in clinical practice.
Objective: This article reviews many of the preclinical innovations in acute kidney injury AKI treatment, and
explores challenges and opportunities to translate these finding into clinical practice.
Sources of Information: MEDLINE, ISI Web of Science
Findings: This paper details areas in biomedical research where translation of pre-clinical findings into clinical trials
is ongoing, or nearing a point where trial design is warranted. Further, the paper examines ways that best practice
in the management of AKI can reach a broader proportion of the patient population experiencing this condition.
Limitations: This review highlights pertinent literature from the perspective of the research interests of the authors
for new translational work in AKI. As such, it does not represent a systematic review of all of the AKI literature.
Implications: Translation of findings from biomedical research into AKI therapy presents several challenges. These
may be partly overcome by targeting populations for interventional trials where the likelihood of AKI is very high,
and readily predictable. Further, specific clinics to follow-up with patients after AKI events hold promise to provide
best practice in care, and to translate therapies into treatment for the broadest possible patient populations.
Keywords: Acute kidney injury, Endoplasmic reticulum stress, Translational research, Kidney transplant, Stem cellsAbrégé
Contexte: L’insuffisance rénale aiguë (IRA), état pathologique important du point de vue clinique, suscite beaucoup
d’intérêt dans le milieu de la recherche biomédicale. On tarde toutefois à transposer les conclusions des recherches
sur ce sujet en modifications substantielles dans la pratique clinique.
Objectifs: Le présent article passe en revue nombre d’innovations précliniques dans le traitement de l’IRA et
explore les défis que pose la transposition des conclusions dans la pratique clinique, ainsi que les occasions d’y
parvenir.
Sources d’informations: MEDLINE, ISI Web of Science
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Conclusion: Le présent rapport expose en détail les domaines de la recherche biomédicale dans lesquels les
conclusions précliniques sont actuellement transposées ou au point où des essais cliniques seront bientôt
justifiés. De plus, le rapport examine des façons d’étendre le recours aux pratiques exemplaires dans la gestion
de l’IRA à un plus grand nombre de patients atteints de cette pathologie.
Limites de l’étude: La présente étude fait état de la littérature du point de vue des champs d'intérêt de
recherche des auteurs pour le travail de transposition en IRA. Elle ne se veut toutefois pas un compte rendu
exhaustif de la littérature scientifique sur l’IRA.
Répercussions: La transposition des conclusions de la recherche biomédicale en traitement de l’IRA pose de
nombreux défis. Ceux-ci peuvent être partiellement surmontés en effectuant des essais interventionnels sur des
populations ciblées parmi lesquelles l’incidence d’IRA est très élevée et prévisible. De plus, le suivi par des cliniques
spécifiques des patients à la suite d’un épisode d’IRA semble prometteur dans le cadre de l’adoption de pratiques
exemplaires et de la transposition des thérapies en traitements pour le plus grand bassin de patients possible.Why is this report/review important?
Acute kidney injury is a common clinical condition,
whose incidence is increasing. It is associated with both
acute and chronic health implications. Unfortunately,
few therapies for acute kidney injury exist, and it is chal-
lenging to translate new potential therapies to clinical
practice.
What are the key messages?
Valley 1 (bench to bedside) barriers may be overcome by
targeting populations for interventional trials where the
likelihood of acute kidney injury is very high and readily
predictable (such as nephrotoxic drugs or delayed graft
function). Valley 2 (research to practice) barriers may be
overcome through more systematic follow-up of acute kid-
ney injury patients to provide evidence-based treatments.
Implications for future research/policy
There are several translational research opportunities in
acute kidney injury to bridge the valley 1 and 2 barriers.
This will require a transdisciplinary and patient-oriented
approach to research and training, which is currently
promoted through the Canadian Institutes of Health Re-
search and the Kidney Research Scientist Core Educa-
tion and National Training program.
Introduction
Acute kidney injury (AKI) is an important healthcare
issue worldwide. It affects 15-20 % of all hospital stays,
with this figure reaching 30-40 % in patients admitted to
critical care units [1, 2]. The incidence of AKI has in-
creased over the last fifteen years, and is expected to
double over the next decade [3]. AKI is associated with a
significant increase in hospital length of stay and mortality
[4]. Individuals who survive to leave the hospital after an
episode of AKI are at persistent risk of adverse outcomes,
including a 10-fold greater risk of chronic kidney disease
(CKD), a 3-fold greater risk of end-stage renal disease(ESRD), and double the risk of premature death [5]. Des-
pite substantial research efforts and resources dedicated to
AKI, few interventions have impacted the prevention,
extension, or recovery of this clinical syndrome [6].
The discrepancy between the new knowledge gained
through biomedical and clinical research and actual im-
provements in patient care or health service organization
for patients suffering from AKI illustrates a major challenge
faced by the Canadian research community. Although
Canada excels in biomedical research capacity and innova-
tions, translation of these innovations into meaningful
patient-based applications is a significant problem. Further,
even when human applications and improvements in
patient care are identified, the translation of this new
knowledge into widespread clinical practice remains
problematic [7]. This conundrum can be represented
by a model depicting two "death valleys" of the biomed-
ical research to clinical practice continuum (Fig. 1). A
major funder of health-related research in Canada, the
Canadian Institutes of Health Research (CIHR), argues
for initiatives that will bring biomedical discoveries to
the bedside (bridging valley 1) and translate findings
from biomedical and clinical research into relevant
healthcare decision making (bridging valley 2) [7]. The
purpose of this review is to address some of the chal-
lenges and opportunities to bridge these two "death val-
leys" in the field of AKI research.
Review
New therapeutic targets for AKI treatment stemming
from biomedical research: bridging valley 1
Over the last few decades, AKI has become the focus of
extensive clinical and basic research efforts. Alongside
the range of risk factors that predispose patients to AKI,
the core pathology may be broken down into degenerative
processes that affect the renal epithelium, vasculature, and
innate and adaptive immune responses leading to worsen-
ing of this condition [8].
Fig. 1 Bridging the "Death Valleys" of the Canadian healthcare landscape. Depiction of the barriers to putting research into practice in the Canadian
healthcare landscape. In order to ensure that the system is sustainable and to enhance health outcomes, it is critical to bridge the gap
between research and clinical practice. Valley 1 depicts the limited ability to translate information from basic biomedical research to clinical
science and knowledge. Valley 2 depicts the inadequacy of the current healthcare system in synthesizing, disseminating and integrating
research results into clinical practice and healthcare decision-making. To bridge the "Death Valleys" of the healthcare landscape, collective
engagement in the strategy from all levels of government and the research community is necessary
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The pathophysiology of AKI includes nephron loss
through tubular epithelial cell programmed cell death,
or apoptosis and renal epithelial cell necrosis that trigger
an immune response. These conditions lead to a cellular
infiltrate resulting in a decline in the kidney’s filtration
capacity [8]. Renal ischemia is one of the major causes
of AKI. The pathogenesis of renal ischemia involves an
acute inflammatory process leading to the increased ex-
pression of cytokines and chemokines [9]. Innate and
adaptive immune cells participate in the renal ischemic
inflammatory response, where T-regulatory cells (Tregs)
play an important role in attenuating immunologic
damage to the kidney by suppressing a tissue destructive in-
flammatory response to self-antigens [10]. These research
findings have been slow to be adapted to clinical research
since Tregs are difficult to isolate and multiply to provide
enough cells for treatment [10]. However, in recent
research efforts, it has been found that the interleukin
(IL)-2/anti-IL-2 complex (IL-2C) mediates the prefer-
ential expansion of Tregs up to 4-fold in vivo [9]. This
study used a mouse model of ischemia reperfusion in-
jury (IRI), showed an improvement in renal function
through a decrease in the rise of serum creatinine and
blood urea nitrogen (BUN) by more than 50 %, with
IL-2C administration. This was accompanied by an at-
tenuation of renal injury score and apoptosis after IRI.
IL-2C was also shown to increase tubular cell proliferation,
and reduce renal fibrosis. As such, IL-2C-induced-Treg-ex-
pansion may be a viable option in clinical trials to decrease
AKI and facilitate renal recovery.
Oxidative Stress
Mitochondrial dynamics are an important component
of AKI. Alterations in mitochondrial function include
fragmentation with reduction in adenosine triphosphate
(ATP)-generating capacity, fission and subsequentapoptosis during the stress of ischemic injury, en-
hanced production of reactive oxygen species (ROS),
and mitochondrial permeability transition-pore opening
[11]. Mitochondrial dysfunction is further characterized
by progressive accumulation of calcium and depression
in oxidative phosphorylation [12]. Mitochondrial dys-
function leads to ROS generation that may mediate
some pathological features of AKI due to acute tubular
necrosis (ATN). Ischemia may lead to ROS production
through mitochondrial dysfunction. To test if ROS
scavenging directed at the mitochondria improved AKI
outcome, the mitochondrial specific ROS scavenger,
Mito-TEMPO, was used. Inulin-based measurements of
glomerular filtration rate (GFR) fell to approximately 25 %
of control in the cecal ligation puncture mouse model of
sepsis-induced AKI [13]. When Mito-TEMPO was dosed
at 10 mg/kg, GFR decline was limited to 50 %, and 96-
hour survival was improved from 40 % to 80 % [13]. An-
other approach taken pre-clinically has been to stimulate
mitochondrial biogenesis through Beta2-adrenergic recep-
tor stimulation with formoterol. This approach improved
renal function as shown by the normalization of serum
creatinine levels to that of sham controls by 144 hours
after IRI in a mouse model [14]. Thus, selectively improv-
ing mitochondrial function can reduce injury and ultim-
ately reverse AKI. As formoterol is a Food and Drug
Administration (FDA) approved therapeutic, safety tri-
als in patients likely to experience AKI may be warranted,
and extension of these trials to interventional randomized
control trials would be advisable.
Endoplasmic Reticulum (ER) Stress
The process of ER stress has been linked to AKI from a
variety of causes, such as ischemia, nephrotoxic drugs or
contrast media [15–19]. ER stress is caused by the accu-
mulation of misfolded proteins in the ER [19]. It has
become clear that ER stress induction in the kidney
Fig. 2 Acute kidney injury due to acute tubular necrosis. Acute tubular necrosis can be the result of nephrotoxins or ischemia to the kidney.
Nephrotoxic drugs, such as tunicmycin, can induce ER stress caused by protein misfolding; while a lack of blood supply to the kidney can cause
oxidative stress in the mitochondria. Both ER stress and oxidative stress have been shown to generate reactive oxygen species, ultimately leading
to acute kidney injury
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stress leading to loss of renal function in AKI is summa-
rized in Fig. 2. Diverse physiological and environmental
stressors are also regulated through heat shock proteins
(HSPs), which are molecular chaperones that are in-
duced in response to cellular stresses that cause protein
misfolding [21]. HSPs transiently bind to polypeptides
to facilitate correct protein folding by preventing the
aggregation of misfolded proteins. In rodent models of
IRI-induced AKI, HSP induction was shown to provide
protection against the increase in BUN and creatinine
levels, preventing the increase in BUN from normal
levels, and reducing the tubular necrosis and cast formation
index from extensive to mild [22]. The beneficial effects of
HSPs were time dependent, and function most efficiently
when increased within 6 hours of the AKI-inducing insult.
HSPs 70s and 90s are of particular importance in the regu-
lation of protein folding, including the protein GRP78 [21].
ER stress-induced AKI has been shown to be associated
with neutral lipid accumulation [23]. GRP78 overexpression
reduces lipid accumulation generated by ER stress [23].
Low molecular weight chemical chaperones have been used
to reduce ER stress and inhibit AKI due to nephrotoxins
[20] and IRI [24].
Nephron epithelial cell loss during AKI results in part
from apoptosis [25], and prolonged or severe ER stressincreases expression of pro-apoptotic mediators including
CHOP/GADD153 [26, 27]. It has been determined that
the induction of ER stress in the kidney results in CHOP/
GADD153 upregulation and ATN, which is strongly
associated with the occurrence of apoptotic cells in the
region of injury. In a mouse model of nephrotoxin-
induced AKI, the low molecular weight chemical
chaperone, 4-phenylbutyrate (4-PBA), reduced tubular
injury score by approximately half [20]. This effect was
accompanied by a reduction in the expression of the
CHOP/GADD153 protein both in the animal model
as well as in human proximal tubular epithelial cells.
Detailed molecular analysis in the human proximal
tubular cell model revealed the direct effect of the
CHOP/GADD153 protein in inducing tubular cell
death. Return to the mouse model, where genetic
disruption of the CHOP/GADD153 protein was per-
formed, showed protection of the kidney from AKI by
both routine pathological assessment, and ultrastruc-
tural analysis. In this study, the move from pre-clinical
animal models to human cell systems illustrates the
next step in translation in biomedical sciences in prep-
aration for first in human trials. Thus, the induction of
ER stress by various pathophysiological mediators may
contribute to AKI through tubular epithelial cell death.
Drugs that inhibit ER stress, such as the molecular
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cing AKI in preclinical studies [20] and have satisfactory
patient safety profiles in patients with liver cirrhosis and
cystic fibrosis [28, 29]. However, no safety profiles exist
for renal patients. Use of these chaperones may repre-
sent the next step in translation from biomedical re-
search to clinical trials in AKI. It is likely that chemical
chaperone therapy would be most efficacious if given
prophylactically in patients at high risk of developing
AKI.
Autoimmunity
Microvascular injury and endothelial dysfunction have
recently emerged as pivotal elements in the pathogenesis
of AKI [8, 30]. Following IRI, endothelial dysfunction/
injury and apoptosis further compromise microcircula-
tory renal blood flow through decreased vasodilatory
capacity [31], coagulation activation and the formation
of microvascular thrombi [31], and increased rolling/ad-
hesion of inflammatory cells [8]. Because the regenera-
tive capacity of endothelial cells in peritubular capillaries
(PTC) appears limited [32], AKI-related endothelial in-
jury and apoptosis lead to PTC rarefaction [32, 33],
interstitial fibrosis, and increase the risk of CKD [34].
Innate immunity, in particular complement activation,
mediates IRI and AKI after kidney transplantation [35].
The concept of ‘innate autoimmunity’ as a participating
factor in IRI has been put forward by Zhang et al. [36].
In murine studies, periods of ischemic stress/hypoxia in-
duced alterations in surface epitopes in the intestines and
skeletal muscles. Binding of a naturally-occurring IgM
antibody to this self-antigen (nonmuscle myosin heavy
chain) activated complement and caused tissue injury [36].
These data suggest that autoimmunity could accelerate
tissue injury due to IRI.
Apoptotic endothelial cells release a C-terminal frag-
ment of perlecan that was named LG3 because of its 3
laminin G motifs [37]. A circulating autoantibody to
LG3, anti-LG3, is elevated pre- and post-transplant in
kidney transplant recipients who experience acute vascu-
lar rejection [38]. In mice, passive transfer of anti-LG3
antibodies increases vascular inflammation and comple-
ment deposition in aortic vascular allografts when the
allograft is made ischemic prior to transplantation [38].
This suggests that anti-LG3 autoantibodies can enhance
the alloimmune response in the presence of ischemic
stress, which may create permissive conditions through
the local expression of LG3 in the vascular wall. Because
microvascular injury is a prominent factor in IRI [8],
Hamelin et al. speculated that pre-transplant anti-LG3
autoantibodies might increase the risk and severity of
delayed graft function (DGF), and their recent prelimin-
ary studies support this hypothesis [39]. If this finding is
confirmed in larger studies, therapeutic modalities suchas intravenous gammaglobulins or plasmapheresis could
eventually be tested to prevent DGF in patients with ele-
vated anti-LG3 levels.
Regenerative medicine and AKI
One of the main challenges for new clinical therapies in
AKI has been the heterogeneous nature and diverse causes
of the disease [8]. The administration of stem/progenitor
cells offers an alternative approach to the targeting of
specific pathophysiological processes. As highly prolifera-
tive cells capable of differentiation into multiple lineages,
progenitor cells have the theoretical ability to travel to the
site of injury and transdifferentiate into healthy, functional
tissue [40]. There have been numerous studies in animals
reporting restoration of function post-AKI following
administration of cells with beneficial effects including
reduced inflammation, accelerated tubular regeneration,
promotion of angiogenesis, and inhibition of apoptosis/
necrosis [40–42].
By far the most widely and consistently employed cell
population for the treatment of AKI is mesenchymal
stromal cells (MSCs), which are heterogeneous, rare
cells that may be found in bone marrow, peripheral
blood, adipose tissue, skeletal muscle, umbilical cord
wall/blood, and amniotic fluid [41]. A recent meta-
analysis of animal studies of MSC therapy in AKI
showed consistent reduction in serum creatinine across
multiple injury models (ischemic, nephrotoxic), sup-
porting their protective effects [43]. In addition to
MSCs, beneficial effects have been reported in animals
treated with hematopoietic stem cells [44], induced
pluripotent stem cells [45], endothelial progenitor cells
[46], and mature endothelial cells [47]. In contrast to
these studies, Burger et al. and others have shown that
certain progenitor populations increase injury in experi-
mental AKI, thereby highlighting the critical need for
careful selection of cells to ensure safe promotion of
recovery [48–50].
A number of ongoing clinical trials are aimed at tran-
sitioning this experimental therapy into clinical use
(transition through valley 1). One study (NCT01602328-
clinicaltrials.gov) is examining effects of a MSC-based
therapy (AC607) in AKI after cardiac surgery, while another
(NCT01275612) is assessing MSCs in cisplatin-induced
AKI. In addition, several studies are examining the effects
of MSCs in kidney transplantation (NCT01429038;
NCT00752479; NCT00658073; NCT00734396). A re-
cently completed phase one study of MSCs for the
treatment of acute allograft rejection after renal trans-
plantation suggested clinical feasibility and safety [51].
Interestingly, the majority of preclinical studies in cell
therapy have reported exceptionally low levels of cell en-
graftment and limited trans-differentiation into damaged
tissue [52, 53]. Such limited engraftment suggests that
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effects. Consistent with this, conditioned media from
MSCs has been shown to provide benefit in AKI [54, 55].
While there has been substantial interest in the role of se-
creted factors released by infused cells, extracellular vesi-
cles may also be important. Extracellular vesicles are
membrane-derived vesicles that are released from cells
into the extracellular space and are increasingly recog-
nized as mediators of cell-cell communication [56]. While
there is not presently a consensus terminology, major clas-
ses include exosomes (40–100 nm in size), microparticles
(100–1000 nm in size) and apoptotic bodies (1–4 um in
size) [56]. Several studies have reported that administra-
tion of extracellular vesicles derived from progenitor pop-
ulations may be beneficial in AKI. Putative mechanisms of
action include the transfer of micro-RNA (miRNA) to in-
jured cells [57, 58]. It is noteworthy that the majority of
the above studies have examined mixed populations of
extracellular vesicles, which contain both exosomes and
microparticles, and the relative contributions of individual
vesicle subpopulations are unclear.
The use of extracellular vesicles may offer several
advantages over whole cell therapy, which may aid in
the translation into clinical therapy. For example, due to
their small size, vesicles may be more likely to reach the
site of injury compared with cells, which can becomeFig. 3 Steps to translate regenerative therapy for acute kidney injury into c
to be overcome in order to translate research into clinical practice. Firstly, t
While beneficial effects have been reported from various cell populations, t
Second, the optimum cell isolation procedure has yet to be identified. Nex
promote recovery is unknown. In order to bring acute kidney injury therapy t
treatments must be proven superior to treatment methods currently in use. T
of cell based therapytrapped in microvascular beds [59]. The relatively small
size of vesicles might thereby eliminate the need for direct
tissue delivery to optimize therapeutic efficacy, a condition
that may be required with whole cells. Vesicles lack
capacity to proliferate, thus reducing the theoretical risk of
spontaneous tumour development post-administration.
Finally, certain vesicle subpopulations (i.e. exosomes)
may have decreased immunogenicity compared with their
cells of origin [60, 61].
Cell therapy has shown therapeutic promise in preclin-
ical studies that, if realized clinically, would be trans-
formative within the field of AKI. Nevertheless, uptake
of this preclinical innovation has been slow and while
the benefits of cell therapy have been established for
over a decade, clinical trials are only recently established.
While this is likely due in part to a greater burden for
regulatory approval, preclinical research has also failed
to address several key steps in the optimization of cell-
based therapy. First, the most effective population of
cells for promoting recovery has not been established
through direct comparison of various cell populations.
Secondly, isolation procedures have not been standard-
ized and the most appropriate source (i.e. allogeneic vs
autologous; peripheral blood vs umbilical cord blood)
has not been established. Third, the most effective route
and timing of delivery is unclear. Finally, questions oflinical practice. Cell-based therapy faces a number of unique barriers
he most effective population of cells to use for therapy is unclear.
here is a need for comparisons of efficacy across different cell types.
t, the optimum route of cell delivery and timing of delivery in order to
o a new level through regenerative medicine, effectiveness of cell-based
he final step addresses long-term follow-up with subjects to ensure safety
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long-term follow-up has only rarely been done in animal
models. Collectively, the failure to address these key
steps has led to a paucity of information essential for
appropriate trial design, without which therapeutic
development is impossible. By contrast, preclinical work
examining extracellular vesicles is at a much earlier
stage. Because of this, preclinical research has the oppor-
tunity to better inform potential clinical studies on
extracellular vesicles in AKI through optimization of
therapy. Such information would lead to improved
design of clinical trials, and a more rapid translation
of results through valleys 1 and 2 into clinical practice
(see Fig. 3).
Promising opportunities for translation of clinical research
findings to everyday clinical practice and service delivery in
AKI: bridging valley 2
As mentioned above, the development of novel thera-
peutic strategies to prevent or treat AKI based on findings
from basic science has been slow, partly because of the
multifactorial pathophysiology of AKI. However, chal-
lenges in the prediction and early identification of this
condition [62] have also contributed to the limited success
of therapeutic innovations in AKI. Elevations in serum
creatinine remain the most common method for diagnosis
of AKI, even though kidney damage precedes increases in
creatinine. Creatinine also cannot differentiate between
the multiple causes of AKI. This creates a situation where
potential therapies can only be tested in patients with
established AKI, where they may be less effective. To
address this challenge, a number of serum and urinary
biomarkers have been evaluated in order to diagnose AKI
at an earlier stage than serum creatinine. A discussion of
these biomarkers and their strengths and limitations has
recently been reviewed [62]. Most are still available only in
the context of research studies, but the FDA has approved
the NephroCheck® test that combines the urinary bio-
markers insulin-like growth factor binding protein 7 and
tissue inhibitor of metalloproteinases 2 [63, 64]. Nephro-
Check® has only been validated in critically ill patients and
has yet to demonstrate an impact on patient outcomes.
Therefore more work remains to determine its exact role
in the diagnosis and treatment of AKI.
Despite these challenges, there are several opportunities
in AKI research to bridge valley 2. These include, AKI
after kidney transplantation and standardizing follow-
up care for AKI survivors to improve long-term patient
outcomes.
Post-transplant AKI
Kidney transplantation is an excellent clinical setting for
translational research on the prevention of AKI, since
the timing of IRI is precisely known. In the immediatepost-transplant period, IRI to the transplanted organ
leads to AKI in 20 %-50 % of transplantations from de-
ceased donors [65–67]. Post-transplant AKI, or DGF, is
associated with an increased risk of acute rejection [68, 69]
and reduced long-term graft survival [68, 70, 71].
Predicting which recipient will develop DGF is import-
ant to provide information to patients and physicians on
the expected post-transplant evolution, and may influ-
ence the selection of induction therapy [72]. In order to
facilitate prediction of DGF, user-friendly tools such as
nomograms [73, 74] have been developed and validated
in kidney transplant patients [75–77]. Web-based risk
calculators for DGF also exist [76, 78], including applica-
tions that can be downloaded on smartphones or tablets
[78]. The availability of these web-based tools is an
excellent example of translation of clinical research to
everyday decision–making. Nevertheless, the predictive
nomograms are not routinely used in clinical practice.
This may be due to their perceived limited clinical
applicability [79]. As immunosuppressive or allocation
strategies that differ according to nomogram scores have
not been tested, physicians may not feel comfortable
modifying their current treatment schemes on the basis
of these scores [79]. This is especially relevant since re-
ported diagnostic accuracies for the existing models are
reasonable but not strong, with C-statistics of 0.71-0.73
[76, 78]. To bridge valley 2, future studies will need to
test the clinical usefulness of the scores for selecting dif-
ferent therapeutic strategies.
One unique aspect of AKI prevention in kidney trans-
plantation is the possibility of managing the donor
and/or the organ before implantation. In the last dec-
ade, an example of successful translation of basic/
clinical research to clinical practice has been the use of
hypothermic machine perfusion instead of static cold
storage to preserve the kidney allograft between pro-
curement and implantation [80]. A recent meta-analysis
shows that use of hypothermic machine perfusion leads
to a relative risk for DGF of 0.81 when compared to
cold storage [81], a figure that increases to 40-45 % rela-
tive risk reductions for DGF in recipients of extended
criteria donors and of donors after cardiac arrest
[82, 83]. Despite proven benefit in the prevention of
DGF, machine perfusion is not being used uniformly
across Canada. Although little data exists on the factors
that limit its use, the latter may include uncertainty
about the cost-effectiveness of machine perfusion [84],
machine availability and cost, or experience and interest
of the surgical team harvesting the organs. The import-
ance of knowledge translation, or raising knowledge
users’ awareness of research findings and facilitating the
use of those findings [85], is increasingly being recog-
nized [86]. Research including all important stake-
holders to gather data on the frequency of machine
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lutions to overcome these barriers is now needed to
truly change everyday clinical practice [86].
Long-term AKI outcomes
One of the barriers to optimal patient care has been that
therapeutic AKI research often focuses on short-term
outcomes (such as 90-day mortality) [87, 88], ignoring
the kidney and cardiovascular morbidity that affects AKI
survivors. This gap in knowledge creation may have re-
sulted in a missed opportunity to improve long-term
outcomes for patients who survive AKI [89]. Without a
standard model for post-AKI care, it is not surprising
that only 40 % of patients who required dialysis for AKI
and recovered sufficient kidney function to stop dialysis
saw a nephrologist within 90-days of hospital discharge
[90]. This represents an important care gap since a
nephrologist visit within 90-days of discharge has been
associated with a 25 % relative mortality reduction com-
pared to patients who do not see a nephrologist after
hospital discharge [90].
In order to more effectively translate evidence-based
recommendations to AKI survivors, an approach taken
by two tertiary hospitals in Toronto, Canada has been the
establishment of an AKI Follow-up Clinic. All hospitalized
patients with a serum creatinine that at least doubled
compared to baseline or who received dialysis for AKI are
potentially eligible for the AKI Follow-up Clinic if they
survive to hospital discharge. Clinic appointments are
arranged within 30-days of discharge, but up to 90-days
is acceptable. Visits consist of a standardized assess-
ment that highlights blood pressure and urine albumin
control, review of quarterly blood work, cardiovascular
risk reduction, and management of kidney disease com-
plications. Evidence-based guidelines are also provided
on the standardized assessment templates for treatment
of CKD [91], hypertension [92], hyperlipidemia [93, 94],
and diabetic nephropathy [95].
While the experiences of the AKI Follow-up Clinic are
preliminary, this intervention offers several opportunities
to translate clinical knowledge into practice. First, AKI
survivor follow-up may present an opportunity to expose
previously unrecognized CKD and establish nephrology
contact [3]. CKD is the most important risk factor for
AKI [96], and a previous cohort demonstrated that 60 %
of AKI survivors have pre-existing CKD and have never
seen a nephrologist [97]. Improving healthcare access for
this population may address some of the barriers associ-
ated with suboptimal dialysis initiation (defined as dialysis
initiation in-hospital and/or temporary vascular access)
[98, 99], thereby reducing healthcare costs and patient
morbidity [100, 101].
Second, the AKI Follow-up Clinic may allow for more
appropriate treatment of CKD and cardiovascularcomplications, since studies suggest that nephrologists
are skilled at recognizing and managing such complica-
tions according to evidence-based guidelines [102, 103].
Potential opportunities for valley 2 translation include
the treatment of hypertension, proteinuria, and hyper-
lipidemia. This is especially important for hospitalized
AKI survivors, since up to 67 % of patients admitted
to hospital have unintended medication discrepancies
at discharge [104, 105]. These discrepancies have been
associated with hospital readmission and death, par-
ticularly for cessation of chronic disease medications
[106]. Thus, an AKI Follow-up Clinic may help maximize
the appropriate use of anti-platelet agents, renin-
angiotensin inhibitors, and statins.
Third, the AKI Follow-up Clinic provides nephrolo-
gists with an opportunity to educate primary care pro-
viders and specialists on AKI and its downstream
complications. It is only now being appreciated that AKI
survivors have similar long-term outcomes as patients
with diabetes and survivors of a ST-elevation myocardial
infarction [107, 108]. Adverse outcomes seem to be
attenuated, but still persist in patients whose serum
creatinine approaches its pre-hospital baseline within
90 days of discharge [109]. Therefore, some experts have
suggested that an “episode of AKI” be documented in a
patient’s past medical history [3]. Incorporating this
recommendation into daily practice will require effective
knowledge translation and education strategies, which
an AKI Follow-up Clinic is well-positioned to accom-
plish through dictated clinic letters.
Despite the theoretical benefits of the AKI Follow-up
Clinic, several challenges to successful translation and
implementation remain. First, the reasons for AKI sur-
vivor non-referral are unknown. This will require broad
stakeholder engagement with healthcare providers, pa-
tients, caregivers, and administrators. Qualitative and
quality improvement methods will be required to design
effective and sustainable AKI survivor referral pathways
[110]. Second, there is no high quality evidence to prove
that the processes implemented in the AKI Follow-up
Clinic will reduce the morbidity or mortality among AKI
survivors. This will require observational and interven-
tional studies to support the potential mechanisms of-
fered above.
If successful in establishing an AKI survivor care path-
way, this clinic could help facilitate translational research
by bringing together basic science and clinical re-
searchers to study the mechanisms of AKI to CKD tran-
sition in a well-defined population. Potential areas of
investigation include the role of fibrosis in AKI [111],
biomarkers of CKD progression [112], and bedside tools
to predict adverse events post-AKI [113, 114]. Such
interdisciplinary collaborations via specialty clinics have
been successful in other disciplines [115], and may also
Silver et al. Canadian Journal of Kidney Health and Disease  (2015) 2:30 Page 9 of 11help nephrology to translate research findings into
health benefits for patients.
Conclusion
In this paper, we have shown examples of successful
translational research, areas where improvement is
urgently needed, and new opportunities for improving
the care of AKI. For the last decade, the Canadian
nephrology research community has responded to the
need for translational research by creating training and
research networks promoting a transdisciplinary approach,
such as the Kidney Research Scientist Core Education and
National Training (KRESCENT) program, the Canadian
National Transplant Research Program (CNTRP), and the
Canadian Kidney Knowledge Translation and Generation
Network (www.CANN-NET.ca). CIHR’s strategy for
patient oriented research is now creating a unique oppor-
tunity for Canada to bring together research professionals
from various orientations and create a nation-wide, in-
tegrated research network in the field of nephrology. In
the future, this network will improve Canada’s success
in bridging the two valleys of the continuum in health
research.
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